← FDA DRUG APPROVALS

FDA ANDA · ANDA208112

METHYLNALTREXONE BROMIDE

Sponsor: ACTAVIS LLC

APPLICATION
ANDA208112
TYPE
ANDA
ORIGINAL APPROVAL
2024-08-26
LATEST ACTION
2024-08-26
ROUTE
SUBCUTANEOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

METHYLNALTREXONE BROMIDEDiscontinued
METHYLNALTREXONE BROMIDE 8MG/0.4ML (8MG/0.4ML) · SOLUTION · SUBCUTANEOUS
METHYLNALTREXONE BROMIDEDiscontinued
METHYLNALTREXONE BROMIDE 12MG/0.6ML (12MG/0.6ML) · SOLUTION · SUBCUTANEOUS

Approval history

2024-08-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →